Astrazeneca (AZN) Fundamental Analysis: Revenue, Earnings & Valuation

7.84 / 10

Outperform

Fundamentally, AZN rates Outperform with a 7.8/10 quality score. ROE stands at 18.2% and annualized ROE 24.3%, cash‑flow growth 36.6% YoY, and profit margins above 18%. Concerns include a sub‑1.0 current ratio and moderate equity multiplier, yet outlook remains very promising.

Analysis Checks(5/10)

Net cash flow from operating activities per share (YoY growth rate %)

Value36.58

Score1/3

Weight0.26%

1M Return2.99%

Annualized return on equity (%)

Value24.30

Score3/3

Weight33.78%

1M Return331.00%

Shareholders’ equity attributable to parent company / Total liabilities (%)

Value0.67

Score0/3

Weight-0.08%

1M Return-1.05%

Total profit (YoY growth rate %)

Value39.12

Score1/3

Weight-0.04%

1M Return-0.54%

Income tax / Total profit (%)

Value19.12

Score2/3

Weight0.60%

1M Return7.56%

ROE (%)

Value18.23

Score3/3

Weight33.78%

1M Return331.00%

Net profit attributable to parent company shareholders (YoY growth rate %)

Value42.71

Score1/3

Weight-0.04%

1M Return-0.48%

Equity multiplier (DuPont analysis %)

Value2.52

Score1/3

Weight-0.01%

1M Return-0.12%

Net profit / Total operating revenue (%)

Value18.28

Score2/3

Weight0.25%

1M Return2.62%

Current ratio

Value0.88

Score3/3

Weight31.51%

1M Return400.85%

Is AZN fundamentally strong?

AZN scores 7.84/10 on fundamentals and holds a Discounted valuation at present. Backed by its 22.83% ROE, 17.42% net margin, 27.85 P/E ratio, 5.84 P/B ratio, and 45.37% earnings growth, these metrics solidify its Outperform investment rating.